Success of Vaccine Offers Promise of Cervical Cancer Prevention

Schultz, James E.

doi:10.1093/jnci/95.2.102

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The worldwide reports on the importance of HPVs as sexually transmitted diseases and its cause-effect relationship with cervical cancer will necessitate the need for HPV mandatory screeing, particularly for HPV-16 and HPV-18, for which a vaccine is available and already approved by the United States Food and Drug Administration. 25 , 26…”

Section: Discussionmentioning

confidence: 99%

Human papilloma virus-16/18 cervical infection among women attending a family medical clinic in Riyadh

Al‐Ahdal

Hassan

Kessie

et al. 2007

Annals of Saudi Medicine

View full text Add to dashboard Cite

BACKGROUNDPrevalence information is lacking on human papillomavirus types 16 and 18 (HPV-16/18) infection in cervical tissues of women residing in Riyadh, Saudi Arabia. In addition, there are no observations on progression to cervical intraepithelial neoplasia (CIN).SUBJECTS AND METHODSPap smear and HPV-16/18 DNA detection by PCR followed by Southern blotting was performed on 120 subjects (Saudi and other Arab nationals) during routine gynecological examination. Some HPV-positive subjects were followed for 4 years, by Pap smear every 6 months and by HPV DNA detection at the end of 4 years.RESULTSOverall HPV-16/18 prevalence was 31.6%. HPV-16 prevalence alone was 13.3%, HPV-16 as a mixed infection with HPV-18 was 15%, and all HPV-16 was 28.3%. HPV-18 alone was 3.3%, HPV-18 as a mixed infection with HPV-16 was 15%, and all HPV-18 was 18.3%. Ten subjects had cervical abnormalities with the Pap smear test, six of whom were HPV-16/18 positive, 1 with HPV-16, 1 with HPV-18, and 4 with a mixed infection of HPV-16/18. Of all 23 HPV-16/18-positive subjects, either as individual or mixed infection, followed for 4 years, 7 showed abnormal cytology, 6 at initial examination and 1 during follow-up. Of these 7, 6 reverted to normal without treatment and 1 was treated and became normal after 3 years. None of the subjects progressed to CIN-III.CONCLUSIONA high prevalence of HPV-16/18 was found, but with a low rate of progression to CIN. A significant association with abnormal cytology was found only in patients with HPV-16/18 mixed infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Human papilloma virus-16/18 cervical infection among women attending a family medical clinic in Riyadh

Al‐Ahdal

Hassan

Kessie

et al. 2007

Annals of Saudi Medicine

View full text Add to dashboard Cite

show abstract

“…HPV 16 and 18 accounted for three‐quarters of cervical cancer cases. Vaccines against HPV 16 and 18, currently under development,34 therefore offer hope for the control of the majority of the disease in this area, if they can be produced and delivered at an affordable cost.…”

Section: Discussionmentioning

confidence: 99%

Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case‐control study

Franceschi

Rajkumar

Vaccarella

et al. 2003

Intl Journal of Cancer

140

111

View full text Add to dashboard Cite

To evaluate the role of human papillomavirus (HPV) and other risk factors in the aetiology of invasive cervical carcinoma (ICC), we conducted a hospital-based case-control study in Chennai, Southern India. A total of 205 ICC cases (including 12 adenocarcinomas) and 213 frequency agematched control women were included. HPV DNA in cervical cells was evaluated by means of a polymerase chainreaction assay. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were computed by means of unconditional multiple logistic regression models. HPV infection was detected in all but one ICC cases and in 27.7% of control women (OR ‫؍‬ 498). Twenty-three different HPV types were found. HPV 16 was the most common type in either cases or controls, followed by HPV 18 and 33. Approximately 125,000 new cervical cancer cases have been estimated to have occurred in India in 2000 (i.e., nearly one-third of all new cervical cancer cases worldwide). 1 Incidence rates in the country, however, varied between 11 per 100,000 in Trivandrum and 30 per 100,000 in Chennai (former Madras), all in Southern India. 2 In Chennai, a woman's estimated probability of developing cervical cancer up to age 74 was more than 3%. As in other developing countries, squamous cell carcinoma predominates, whereas adenocarcinoma of the cervix accounts for a small percent of all cervical cancer, even in the urban areas (e.g., Mumbai, 7%). 3 A high prevalence of human papillomavirus (HPV) 16 and 18 in cervical cancer specimens has been shown in India 2 as elsewhere, 4 but limited information is available on the distribution of HPV types in the country.Case-control studies on invasive cervical carcinoma (ICC) in India have been relatively few. 6 -11 Low educational and socioeconomic level, young age at marriage or first sexual intercourse, high parity and male partner's sexual behaviour were the most consistently reported risk factors. No case-control study from India has provided thus far an estimate of the association between cervical cancer and infection with HPV, the necessary cause of the disease worldwide. 12 To further elucidate the role of different HPV types and its co-factors in ICC aetiology, we carried out a case-control study in Chennai, Southern India. MATERIAL AND METHODSOur study is part of an international multicenter case-control study of ICC and HPV coordinated by the International Agency for Research on Cancer (IARC). 13 From June 1998 to May 1999, 222 women with a diagnosis of ICC were recruited into the Cancer Institute in Chennai, Southern India. 14 On account of the high burden of ICC cases at the Cancer Institute, the first woman to be newly diagnosed with ICC each working day was asked to participate in our study and was administered an informed consent. Inclusion criteria for case subjects were: (i) histologic confirmation of ICC diagnosis; (ii) no previous cancer treatment; and (iii) lack of physical or mental impairments that would have made the interview impossible. Seventeen women were excluded based on the revision of histol...

show abstract

“…In animals, immunization with HPV virus‐like particles produced an immune response that neutralized the intact virus. Within the last year, prophylactic vaccines for HPV‐16 and ‐18 have progressed to large‐scale human trials (110). The HPV vaccine is designed to induce cellular immunity targeted to HPV proteins.…”

Section: Less Commonly Employed Therapiesmentioning

confidence: 99%

Therapy of external anogenital warts and molluscum contagiosum: a literature review

Ting

Dytoc

2004

Dermatol Ther

View full text Add to dashboard Cite

Anogenital warts and mollusca contagiosum are virally induced, benign skin tumors for which there is no single preferable therapy. Treatments include physical and chemical destruction, surgical removal, and biological response modifiers to enhance the natural immune response. The choice of therapy is an art, and depends upon patient preference, finances, number of lesions, and lesional morphology. However, the therapy of these lesions can sometimes be very painful and expensive, and therapy should not be worse than the disease.

show abstract

Success of Vaccine Offers Promise of Cervical Cancer Prevention

Cited by 9 publications

References 0 publications

Human papilloma virus-16/18 cervical infection among women attending a family medical clinic in Riyadh

Human papilloma virus-16/18 cervical infection among women attending a family medical clinic in Riyadh

Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case‐control study

Therapy of external anogenital warts and molluscum contagiosum: a literature review

Contact Info

Product

Resources

About